Combination therapy for advanced stomach cancer after immunotherapy
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your cancer is advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- You have already tried at least one immunotherapy (like Keytruda or Opdivo) and your cancer either did not respond or you had side effects.
- You have not had more than two different types of treatment for advanced cancer.
- Your tumors can be measured on a scan (like CT or MRI).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
This trial tests a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. It is designed for those whose tumors have low PD-L1 levels.
This trial tests whether adding an immunotherapy drug (adebrelimab) with or without another targeted drug (apatinib) to standard chemotherapy is more effective for advanced stomach cancer. It aims to shrink tumors and improve outcomes for people who haven't had prior treatment for advanced disease.
This study tests a new combination of drugs (apatinib, nab-paclitaxel, and possibly adebrelimab) for advanced stomach or gastroesophageal junction cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This study tests a combination of three drugs (adebrelimab, apatinib, and paclitaxel) for people with advanced stomach or GEJ cancer that continued to grow after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.